The importance of NTRK gene fusion testing and the FastTRK program
FastTRK is a clinical testing program for the diagnosis of NTRK gene fusions. Sponsored by Bayer, this is a complimentary service for clinicians to determine whether their patients’ cancer has an NTRK gene fusion.
The program has been recently updated to offer upfront NGS testing for select solid tumour types. For more information on NTRK gene fusions or about the FastTRK program please select the links below.